GICS Sector : Healthcare
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies.It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases.The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Avidity Biosciences (NASDAQ:RNA) Sets New 52-Week Low – Here’s Why
Mar -02
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
Feb -27
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Feb -26
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders
Feb -23
Fiera Capital Corp Has $52.39 Million Position in Avidity Biosciences, Inc. $RNA
Feb -20
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
Feb -18
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Recommendation of “Hold” from Brokerages
Feb -06
Avidity Biosciences Announces Expected Record Date for Spin-Off
Feb -03
Avidity Biosciences' Antibody Oligonucleotide Conjugates' 12.05% growth is driven by increasing adoption in targeted therapies, rising demand for precision medicine, and advancements in RNA-based treatments. Strong partnerships, expanding pipeline, and growing investments in gene therapy research also contribute to this growth.
AOC 1001 is a phosphorothioate oligonucleotide that selectively targets and inhibits the expression of a specific gene, which is associated with various diseases.
AOC 1020 is a phosphorothioate oligonucleotide that selectively targets and inhibits the expression of a specific gene, which is associated with various diseases.
AOC 1044 is a phosphorothioate oligonucleotide that selectively targets and inhibits the expression of a specific gene, which is associated with various diseases.
AOC 1067 is a phosphorothioate oligonucleotide that selectively targets and inhibits the expression of a specific gene, which is associated with various diseases.
Avidity Biosciences, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the biotechnology industry.
Avidity Biosciences, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are highly specialized, making it difficult for customers to switch to alternative suppliers.
Avidity Biosciences, Inc. relies on a few key suppliers for raw materials and equipment. While the company has some bargaining power due to its size and reputation, the suppliers still have some leverage due to the specialized nature of the products.
The biotechnology industry has high barriers to entry, including significant capital requirements, complex regulatory frameworks, and the need for specialized expertise. These barriers make it difficult for new entrants to compete with established companies like Avidity Biosciences, Inc.
The biotechnology industry is highly competitive, with many established companies competing for market share. Avidity Biosciences, Inc. faces intense competition from companies with similar products and technologies, which can lead to pricing pressure and reduced market share.
| Value | |
|---|---|
| Debt Weight | 1.93% |
| Debt Cost | 3.95% |
| Equity Weight | 98.07% |
| Equity Cost | 7.87% |
| WACC | 7.80% |
| Leverage | 1.97% |
Value: 6.0
Growth: 7.1
Quality: 5.2
Yield: 0.0
Momentum: 9.0
Volatility: 6.3
1-Year Total Return ->
Value: 6.2
Growth: 4.6
Quality: 5.0
Yield: 0.0
Momentum: 8.0
Volatility: 2.0
1-Year Total Return ->
Value: 6.2
Growth: 2.7
Quality: 5.1
Yield: 0.0
Momentum: 10.0
Volatility: 1.3
1-Year Total Return ->
Value: 8.7
Growth: 7.9
Quality: 5.1
Yield: 0.0
Momentum: 0.0
Volatility: 1.0
1-Year Total Return ->
Value: 7.6
Growth: 4.2
Quality: 5.1
Yield: 0.0
Momentum: 0.0
Volatility: 2.0
1-Year Total Return ->
Value: 6.4
Growth: 1.1
Quality: 5.1
Yield: 0.0
Momentum: 1.5
Volatility: 2.7
1-Year Total Return ->